{
    "clinical_study": {
        "@rank": "166525", 
        "arm_group": [
            {
                "arm_group_label": "Montelukast", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Vitamin B6", 
                "arm_group_type": "Sham Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Montelukast is one of anti-inflammatory agents and a good controller for the patients with\n      asthma. The hypothesis of the study is that the Montelukast will have airway\n      anti-inflammatory effects and up-regulated regulatory T cells functions in asthma."
        }, 
        "brief_title": "Effects of Montelukast on Airway Regulatory T Cells in Asthma", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  asthma\n\n          -  mild status\n\n          -  stable status\n\n          -  nonsmoker\n\n          -  Positive of airway hyperresponsiveness (Methacholine-PC20<16mg/mL)\n\n        Exclusion Criteria:\n\n          -  taken other asthmatic medications such as oral, injective, and inhaled steroids,\n             leukotriene antagonists, oral, inhaled, and transdermal beta-agonists, theophylline,\n             anti-histamine agents, anti-IgE antibodies and long acting muscarinic receptor\n             antagonists.\n\n          -  respiratory tract infections within 4wks\n\n          -  moderate to severe other organ disorders\n\n          -  active malignancies\n\n          -  past histories of side effects of leukotriene antagonists\n\n          -  psychological disorders\n\n          -  pregnancy or nursing"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01951898", 
            "org_study_id": "KU-012012"
        }, 
        "intervention": {
            "arm_group_label": [
                "Montelukast", 
                "Vitamin B6"
            ], 
            "description": "10mg/day, once a daily after dinner, for 28dyas", 
            "intervention_name": "Montelukast", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Montelukast", 
                "Leukotriene Antagonists"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "asthma", 
            "regulatory T cells", 
            "leukotriene antagonist"
        ], 
        "lastchanged_date": "September 24, 2013", 
        "location": {
            "contact": {
                "last_name": "Tomotaka Kawayama, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Kurume", 
                    "country": "Japan"
                }, 
                "name": "Kurume University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Tomotaka Kawayama, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Effects of Montelukast on Airway Foxp3+ and CTLA4+CD25highCD4+ T Cells in Asthmatics", 
        "overall_contact": {
            "email": "kawayama_tomotaka@med.kurume-u.ac.jp", 
            "last_name": "Tomotaka Kawayama, MD", 
            "phone": "+81-942-31-7560"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Pharmaceuticals and Medical Devices Agency"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Montelukast will up-regulate airway regulatory T cell in the patients with asthma", 
            "safety_issue": "Yes", 
            "time_frame": "4wks of treatment period"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01951898"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Kurume University", 
            "investigator_full_name": "Tomotaka Kawayama", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "Montelukast will improve airway inflammation, lung function and hyperresponsiveness in the patients with asthma", 
            "safety_issue": "Yes", 
            "time_frame": "4wks of treatment periods"
        }, 
        "source": "Kurume University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Kurume University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}